| 摘要 |
The present invention provides solid dosage formulations of benzoxazole-containing ERbeta-selective ligands, and processes for their manufacture, more particularly to novel formulations, and processes for their manufacture, that contain the ERbeta-selective ligand, ERB-041.
|
